COMMUNIQUÉS West-GlobeNewswire
-
A.D.A.M. Innovations Enables Pharmacogenomics for NTT Precision Medicine
30/04/2026 -
Former Stryker Medical Division President Brad Saar Joins Sonablate Board to Support Growth of Non-Invasive Prostate Cancer Treatment
30/04/2026 -
Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets
30/04/2026 -
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
30/04/2026 -
Willow Glow Wellness Spa Clinics Announces Advanced LED Facelift Protocol, Attracting Silicon Valley Clients for Non-Surgical Skin Rejuvenation
30/04/2026 -
Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors
30/04/2026 -
Oncotelic Therapeutics Advances Toward Commercial Launch of AI-Enabled Robotics Platform Following Integration of 28 Million Scientific Abstracts
30/04/2026 -
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
30/04/2026 -
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
30/04/2026 -
Kraig Labs Clears Dual Commercialization Milestones with Record Spider Silk Production and Successful Reeling Operations
30/04/2026 -
Centre for Neuro Skills CEO David Harrington Joins Brain to Brain Podcast to Discuss the Science of Recovery, Advocacy for Brain Injury Care and Why It Is Never Too Late
30/04/2026 -
YouthCommerce Unveils PhiFlow: A Revolutionary Operating Standard for Clinics
30/04/2026 -
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
30/04/2026 -
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
30/04/2026 -
TimelyCare Expands Its Basic Needs Service to Help Colleges Better Support Student Retention
30/04/2026 -
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026
30/04/2026 -
UREVO Wins iF Design Award 2026 for AI-Powered Wireless Recovery Boots
30/04/2026 -
Verano Announces $20 Million Share Repurchase Authorization
30/04/2026 -
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
30/04/2026
Pages